HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a price target of $13.
December 07, 2023 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reaffirmed a Buy rating on Coherus BioSciences with a $13 price target.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can instill confidence in investors and positively influence the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100